Comprehensive Solutions for Your Biotherapeutic and Vaccine Programs
At Emergent, our drug substance development teams are ready to work closely with you to deliver a solution honed to your specific needs. We help biopharma organizations in all program phases successfully manage the development and scale-up of cGMP-compliant drug substance processes.
With more than 20 years of process development experience, Emergent CDMO provides its clients with distinct advantages for their biological programs:
- Proteins (recombinant, plasma, fusion)
- Antibodies (mAb, antibody fragments)
- Viruses (live and live-attenuated)
- Viral vectors
- Recombinant viruses
- Gene therapy
- Nanoparticle platforms